Merrick I. Ross

机构：The University of Texas MD Anderson Cancer Center · ORCID：0000-0002-7787-0421

发表论文 623 篇 · 总被引 58946 次 · h-index 112

代表论文

• NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024 (2024 · Journal of the National Comprehensive Cancer Network · 被引 158)
• Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial (2024 · Nature Communications · 被引 32)
• Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma (2025 · Journal of Clinical Oncology · 被引 15)
• Spitz melanocytic neoplasms with MLPH::ALK fusions: Report of two cases with previously unreported features and literature review (2024 · Journal of Cutaneous Pathology · 被引 10)
• Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma (2025 · OncoImmunology · 被引 9)
• Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial (2025 · Annals of Surgical Oncology · 被引 5)